ScreenerHero

TRMED Thor Medical ASA

OSL · NO · Healthcare · Biotechnology · thormedical.no
4.415NOK-1.89%Mkt Cap: 174.37M $P/E: —

Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 200…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap174.37M USD
Enterprise Value168.48M USD
Revenue (TTM)153.21K USD
Gross Profit153.21K USD
Net Income (TTM)-5.42M USD
Revenue/Share0.0050 NOK
Last Price4.415 NOK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees24
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0010597883
Valuation
P/E (Trailing)—
P/E (Forward)-45.00
PEG—
EV/EBITDA-29.97
EV/Revenue1099.64
P/S1160.01
P/B3.49
EPS (TTM)-0.23
EPS (Forward)-0.10
52W Range
3.17531% of range7.120
52W High7.120 NOK
52W Low3.175 NOK
Profitability
Gross Margin100.00%
Oper. Margin-5155.56%
EBITDA Margin0.00%
Profit Margin-13214.58%
ROE-12.72%
ROA-8.19%
Growth
Revenue Growth800.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.44M USD
CapEx (TTM)6.83M USD
FCF Margin-12606.70%
FCF Yield-11.08%
Net Debt17.04M USD
Net Debt/EBITDA-3.03
Balance Sheet
Debt/Equity0.38
Current Ratio2.89
Quick Ratio1.85
Book Value/Sh1.29 NOK
Cash/Share0.17 NOK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 NOK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.200 NOK
Upside (mean)-4.9%
Target Range4.200 NOK – 4.200 NOK
# Analysts1
Ownership
Shares Out.422.50M
Float204.18M
Insiders35.92%
Institutions7.05%
Technical
SMA 505.313 (-16.9%)
SMA 2004.784 (-7.7%)
Beta-0.24
S&P 52W Chg14.58%
Avg Vol (30d)8.05M
Avg Vol (10d)3.58M
Technical Indicators
RSI (14)37.5
MACD-0.2301
MACD Signal-0.2291
MACD Hist.-0.0010
BB Upper4.956 NOK
BB Middle4.655 NOK
BB Lower4.355 NOK
BB Width12.90%
ATR (14)0.2123 NOK
Vol Ratio (20d)0.19x